Akums Drugs and Pharmaceuticals Reports ₹66.65 Crore Net Profit in Last Quarter

Akums Drugs and Pharmaceuticals Ltd. has announced its financial results, with a net profit of ₹66.65 crore for the last quarter. The company typically releases its quarterly results around mid-July for Q1, mid-October for Q2, mid-January for Q3, and mid-April for Q4.

 

For the quarter ended September 2024, Akums Drugs and Pharmaceuticals Ltd. reported a net profit of ₹667 million. In Q2FY25, the adjusted net profit rose 16% year-over-year to ₹66.7 crore, despite an 11.9% decline in revenue to ₹1046.6 crore due to lower API prices and fluctuating demand. Adjusted EBITDA was recorded at ₹1,347 million, a 28% drop from the previous quarter, with an adjusted EBITDA margin of 12.9%.

 

The company remains optimistic about stabilizing as it expands its footprint, with a robust cash surplus position of ₹340.6 crore to support further investment in R&D and business capabilities. Sanjeev Jain, Managing Director, noted the strong secular demand for outsourced drug development and manufacturing.

 

Source: blinkx.in, Economic Times, Equity Master